Stroke Market Analysis, Size, Share & Growth Forecast 2026–2034

Tenecteplase Single-Bolus IV Thrombolysis Demonstrating Equivalent or Superior Recanalization Versus 60-Minute Alteplase Infusion in ATTEST-2 and NOR-TEST 2 Has Provided the Emergency Setting Pragmatic Advantage That Telemedicine Stroke Protocols Prefer for the Single-Administration Treatment.DAWN and DEFUSE 3 trials demonstrated that perfusion imaging-guided selection of patients with salvageable ischaemic penumbra at 6-24 and 6-16 hours respectively could identify patients with enduring large-vessel-occlusion who benefit from thrombectomy at delayed time points where routine treatment was previously considered ineffective. The clinical implication is that patient eligibility for thrombectomy is determined by perfusion CT or MRI imaging rather than time from onset alone, requiring rapid imaging implementation that has driven adoption of RAPID automated perfusion analysis software at comprehensive stroke centres. Stryker Trevo, Medtronic Solitaire, and Penumbra JET stent-retriever systems generate combined thrombectomy market revenue exceeding USD 1.5 billion annually, growing proportionally with expanded eligibility windows and increased public awareness campaigns that reduce last-known-well-to-door time.

DAWN and DEFUSE-3 Extended Window Mechanical Thrombectomy to 24 Hours Using Penumbral Imaging Selection Achieving 73 to 78 Percent mRS 0 to 2 Has Extended the Reperfusion Treatment Window From the Previous 6-Hour Standard to the Imaging-Selected Salvageable Tissue That Persistent Penumbra Defines.Phase 3 trials including NOR-TEST, AcT, and TRACE-3 have established tenecteplase non-inferiority to alteplase for acute ischaemic stroke reperfusion with the practical advantage of single intravenous bolus administration versus alteplase's 60-minute infusion, reducing the pharmacist preparation and nursing infusion monitoring requirements that delay treatment in community hospitals. The simplified tenecteplase administration enables air and ground transport administration before hospital arrival, extending effective reperfusion to patients in transit who previously could not receive thrombolysis until after hospital arrival and CT imaging confirmation. Genentech's alteplase Activase patent expiry combined with tenecteplase's generic availability in 0.25 mg/kg weight-based dosing has reduced thrombolysis acquisition costs and enabled community hospitals without pharmacy infrastructure for alteplase protocol management to participate in stroke reperfusion therapy.

COMPASS Low-Dose Rivaroxaban Plus Aspirin 24 Percent Cardiovascular Event Reduction Including Stroke Versus Aspirin Alone in Stable Atherosclerotic Disease Has Established the Dual Pathway Anticoagulant Plus Antiplatelet Secondary Prevention for the High-Risk Vascular Disease Patient.The POINT and CHANCE trials demonstrated that 21-90-day dual antiplatelet therapy with aspirin plus clopidogrel reduces stroke recurrence by approximately 25% versus aspirin monotherapy in the high-risk period after minor ischaemic stroke or TIA, establishing short-course DAPT as standard of care in a patient population where stroke recurrence risk is 10-15% within 90 days. Ticagrelor-aspirin short course demonstrated equivalent or superior benefit to clopidogrel-aspirin in THALES and TEMPO-2 trials, providing an alternative DAPT regimen for the approximately 25% of patients with CYP2C19 poor-metaboliser status where clopidogrel's effectiveness is reduced by impaired conversion to active thiolactone metabolite. Anticoagulation with dabigatran, apixaban, and rivaroxaban for non-cardioembolic ischaemic stroke has not demonstrated net benefit over antiplatelet therapy in ESUS and related trials, establishing antiplatelet rather than anticoagulant therapy as the standard for non-AF secondary stroke prevention.

For related market intelligence, see the Cardiology Drug Market.